Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07425821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Nov 2027 to Apr 2027
    • Study completion moved earlier from Jul 2028 to Oct 2027
    • Eligibility criteria expanded, about 25 words
    • Study title shortened, about 6 words
  2. Recruitment opened
    • Study sites: 3 to 2
    • Start date changed from estimate of Mar 2026 to Mar 27, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Trial Details
NCT Number NCT07425821
Lead Sponsor International AIDS Vaccine Initiative
Collaborators: Biomedical Advanced Research and Development Authority
Conditions
(from sponsor)		 Marburg Virus Disease
Related terms Marburg Virus Disease
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov